Korean Biopharmas Set For Another Record Year Of Licensing Deals
More Big Transactions By Year-End?
Scrip takes a look at South Korea’s out-licensing deal trends for 2021, finding that more big transactions are likely as the year moves towards its close despite a wider global slowing in activity, helped by rising innovative R&D.
